Ignite Creation Date:
2024-05-06 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05739630
Status:
RECRUITING
Last Update Posted:
2023-02-22
First Post:
2023-02-13
Brief Title:
M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia
Sponsor:
The First Affiliated Hospital of Soochow University
Organization:
The First Affiliated Hospital of Soochow University
Study Overview
Official Title:
An Multicenter Randomized Controlled Prospective Clinical Study of Mitoxantrone Liposome Combined With PTCy as Conditioning Regimen in Allo-HSCT in Acute Leukemia
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study intends to evaluate the efficiency and safety of M-PTCy as conditioning regimen in Haploidentical HSCT for Acute Leukemia so as to provide a new conditioning regimen for allogeneic hematopoietic cell transplantation
Detailed Description:
Haploidentical related donor transplantation is now considered an important alternative to allogeneic hematopoietic stem cell transplantation allo-HSCT Posttransplant cyclophosphamide PTCy has revolutionized Haplo HCT with acceptable rates of engraftment graft-versus-host disease GVHD relapse and survivalTo prolonger PFS OS and alleviate GVHD we combined Mitoxantrone liposomes with PTCy as conditioning regimen in allogeneic hematopoietic cell transplantation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None